93635-76-8

Basic information

• Product Name: D-Arabinonic acid, 2-C-methyl-4,5-O-(1-methylethylidene)-,ethyl ester
• Synonyms: D-Arabinonic acid, 2-C-methyl-4,5-O-(1-methylethylidene)-,ethyl ester;D-Arabinonic acid, 2-C-Methyl-4,5-O-(1-Methylethylidene)-,ethyl;(2S,3R)-3-((4R)-2,2-DiMethyldioxolan-4-yl)-2-Methyl-2,3-dihydroxypropanoic acid ethyl ester;4,5-O-isopropylidene-2-C-Methyl-D-arabinonate;ethyl (2S,3R)-3-[(4R)-2,2-diMethyl-1,3-dioxolan-4-yl]-2,3-dihydroxy-2-Methyl-propanoate;(2S,3R)-Ethyl 3-((R)-2,2-diMethyl-1,3-dioxolan-4-yl)-2,3-dihydroxy-2-Methylpropanoate;3-(2,2-Dimethyl-[1,3]dioxolan-4-yl)-2,3-dihydroxy-2-methyl-propionic acid ethyl ester;-2,3-dihydroxy-2-methylpropanoate
• CAS NO: 93635-76-8
• Molecular Formula: C₁₁H₂₀O₆
• Molecular Weight: 248.273
• EINECS: 1592732-453-0
• Product Categories: API intermediates
• Mol File: 93635-76-8.mol

Chemical Properties

• Melting Point: 75.0-75.5℃
• Boiling Point: 361.451°C at 760 mmHg
• Flash Point: 133.189°C
• Appearance: /
• Density: 1.186g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.475
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 12.29±0.29(Predicted)
• CAS DataBase Reference: D-Arabinonic acid, 2-C-methyl-4,5-O-(1-methylethylidene)-,ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: D-Arabinonic acid, 2-C-methyl-4,5-O-(1-methylethylidene)-,ethyl ester(93635-76-8)
• EPA Substance Registry System: D-Arabinonic acid, 2-C-methyl-4,5-O-(1-methylethylidene)-,ethyl ester(93635-76-8)

Safety Data

• Hazardous Substances Data: 93635-76-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
D-Arabinonic acid, 2-C-methyl-4,5-O-(1-methylethylidene)-,ethyl ester is used as a key intermediate in the synthesis of 2''-deoxy-2''-fluoro-2''-C-methylcytidine (I), also known as PSI-6130. D-Arabinonic acid, 2-C-methyl-4,5-O-(1-methylethylidene)-,ethyl ester is a potent and selective inhibitor of the Hepatitis C Virus (HCV) NS5B polymerase, an essential enzyme for viral replication. By targeting this enzyme, PSI-6130 can effectively suppress the replication of the virus, making it a promising candidate for the treatment of Hepatitis C.
Furthermore, D-Arabinonic acid, 2-C-methyl-4,5-O-(1-methylethylidene)-,ethyl ester also has potential applications in the synthesis of related antiviral agents. Its unique structure allows for the development of novel compounds with improved antiviral properties, potentially leading to more effective treatments for various viral infections. The versatility of this compound makes it an invaluable asset in the ongoing fight against viral diseases.

InChI:InChI=1/C11H20O6/c1-5-15-9(13)11(4,14)8(12)7-6-16-10(2,3)17-7/h7-8,12,14H,5-6H2,1-4H3/t7-,8-,11+/m1/s1

Upstream product

• 93714-03-5 ethyl trans-2,3-dideoxy-4,5-O-isopropylidene-2-C-methyl-DL-glycero-pent-2-enonate 
• 93714-02-4 ethyl cis-2,3-dideoxy-4,5-O-isopropylidene-2-C-methyl-DL-glycero-pent-2-enonate 
• 81997-75-3 ethyl trans-2,3-dideoxy-4,5-O-isopropylidene-2-C-methyl-D-glycero-pent-2-enonate 
• 81997-76-4 (S,E)-3-(2,2-dimethyl-1,3-dioxolan-4-yl)-2-methylpropionic acid ethyl ester 
• 21382-82-1 (carbethoxyethylidene)triphenylphosphorane 
• 15186-48-8 2,3-isopropylidene-glyceraldehyde 
• 130606-67-6 C₁₁H₁₈O₄ 
• 81997-75-3 ethyl (Z)(R)-4,5-O-isopropylidene-4,5-dihydroxy-2-methylpent-2-enoate 

Downstream Products

• 93636-21-6 3,4-O-isopropylidene-2-C-methyl-DL-arabinono-1,5-lactone 
• 93636-20-5 ethyl 2,3:4,5-di-O-isopropylidene-2-C-methyl-DL-arabinonate 
• 492-30-8 2-C-methyl-DL-arabinono-1,4-lactone 
• 492-30-8 2-C-methyl-DL-lyxono-1,4-lactone 
• 879551-04-9 (3R,4R,5R)-3?fluoro?4?hydroxy?5?(hydroxymethyl)?3?methyltetrahydrofuran?2?one 
• 874638-80-9 ((2R,3R,4R)-3-benzoyloxy-4-fluoro-4-methyl-5-oxo-tetrahydrofuran-2-yl)methyl benzoate 
• 879551-01-6 (4S,5R)-ethyl-5-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-4-meth-yl-1,3,2-dioxathiolane-4-carboxylate 2,2-dioxide 
• 1596350-90-1 C₂₂H₂₄N₄O₃ 
• 1596350-94-5 C₂₃H₂₆N₆O₃ 
• 1596350-95-6 C₂₅H₂₆N₈O₃ 
• 1403574-26-4 C₂₀H₁₇N₃O₆ 
• 1596350-41-2 C₂₀H₂₁N₃O₄ 
• 1596350-43-4 C₂₇H₂₈N₆O₃S 
• 1596350-44-5 C₂₆H₂₇N₇O₃ 

Relevant articles and documents

BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E

The present disclosure is directed toward bi- and monocyclic nucleoside analogs, and compositions comprising these compounds for use in the treatment of hepatitis E infections.

Preparation method of 2-C-methyl-4, 5-O-(1-methylvinyl)-D-arabitic acid ethyl ester

The invention discloses a preparation method of 2-C-methyl-4, 5-O-(1-methylvinyl)-D-arabitic acid ethyl ester (formula I). Compared with the prior art, the preparation method has short reaction steps,reduces the use of organic solvents and generation of solid waste. At the same time, the used reagents are all conventional reagents, the method has the characteristics of simple operation, mild reaction conditions and environmental friendliness, and can achieve industrial preparation of 2-C-methyl-4, 5-O-(1-methylvinyl)-D-arabitic acid ethyl ester.

A preparation process of rope non-cloth wei improved method

The invention provides a method for improving technique of rope non-cloth wei, for the oxidation of olefinic bond when [...], the oxidizing agent is potassium permanganate into sodium permanganate, product yield from 78% improved to 90% or more; in cytosine with halo ethylthio butt coupling reaction using tin tetrachloride to replace the zinc chloride catalytic, yield from 75% to a 88%; using five fluoro phenol instead of the nitro phenol to prepare phosphoric acid ester side chain, so that the phosphoric acid ester side chain of the yield from 80% up to 95%.

Dihydroxylation of Olefins with Potassium Permanganate Catalyzed by Imidazolium Salt

The development of an efficient and cost-effective cis -dihydroxylation reaction of acrylate derivatives was achieved. The reaction proceeded in acetone with an imidazolium salt as catalyst to furnish the dihydroxylation of olefins at 0-5 °C using KMnO 4 as the oxidant. This efficient and non-aqueous protocol was highly suitable for the large-scale preparation of cis -dihydroxylated compounds from the corresponding acrylate derivatives in high yields without overoxidation.

Method for preparing intermediate of Sofosbuvir

The invention provides a method for preparing 3,5-bis-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-D-ribose-gamma-lactone of D-ribofuranose lactone (structural formula 1). The compound is an important intermediate of a hepatitis C virus (HCV) NS5B polymerase inhibitor Sofosbuvir. The formula 1 is shown in the specification.

An Efficient and Practical Method for Olefin Dihydroxylation

An efficient and economic procedure was developed for the dihydroxylation of various olefin derivatives with commercial KMnO4 as the oxidant in the presence of a quaternary ammonium salt. This practical procedure is suitable for large-scale production of cis-dihydroxy compounds, even those bearing primary and secondary alcohol groups, without overoxidation.

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.

2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

Compounds of Formula (I) are disclosed, wherein R1, R2, R3, R4, R5, and R18 are defined herein. The compounds encompassed by Formula (I) include compounds which are HCV NS5B inhibitors and other compounds which can be metabolized in vivo to HCV NS5B inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.